176 related articles for article (PubMed ID: 20706624)
21. New tools for old drugs: Functional genetic screens to optimize current chemotherapy.
Gerhards NM; Rottenberg S
Drug Resist Updat; 2018 Jan; 36():30-46. PubMed ID: 29499836
[TBL] [Abstract][Full Text] [Related]
22. Perturbation biology nominates upstream-downstream drug combinations in RAF inhibitor resistant melanoma cells.
Korkut A; Wang W; Demir E; Aksoy BA; Jing X; Molinelli EJ; Babur Ö; Bemis DL; Onur Sumer S; Solit DB; Pratilas CA; Sander C
Elife; 2015 Aug; 4():. PubMed ID: 26284497
[TBL] [Abstract][Full Text] [Related]
23. Beyond the limitation of targeted therapy: Improve the application of targeted drugs combining genomic data with machine learning.
Miao R; Chen HH; Dang Q; Xia LY; Yang ZY; He MF; Hao ZF; Liang Y
Pharmacol Res; 2020 Sep; 159():104932. PubMed ID: 32473309
[TBL] [Abstract][Full Text] [Related]
24. A decision support framework for genomically informed investigational cancer therapy.
Meric-Bernstam F; Johnson A; Holla V; Bailey AM; Brusco L; Chen K; Routbort M; Patel KP; Zeng J; Kopetz S; Davies MA; Piha-Paul SA; Hong DS; Eterovic AK; Tsimberidou AM; Broaddus R; Bernstam EV; Shaw KR; Mendelsohn J; Mills GB
J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 25863335
[TBL] [Abstract][Full Text] [Related]
25. Update on targeted cancer therapies, single or in combination, and their fine tuning for precision medicine.
Bashraheel SS; Domling A; Goda SK
Biomed Pharmacother; 2020 May; 125():110009. PubMed ID: 32106381
[TBL] [Abstract][Full Text] [Related]
26. Novel Treatments in Development for Melanoma.
Bernatchez C; Cooper ZA; Wargo JA; Hwu P; Lizée G
Cancer Treat Res; 2016; 167():371-416. PubMed ID: 26601872
[TBL] [Abstract][Full Text] [Related]
27. Cancer Therapeutic Resistance: Progress and Perspectives (April 7-8, 2016 - Barcelona, Spain).
Hutchinson E; Pujana MA; Arribas J
Drugs Today (Barc); 2016 Jun; 52(6):347-54. PubMed ID: 27458611
[TBL] [Abstract][Full Text] [Related]
28. Translational modeling and simulation approaches for molecularly targeted small molecule anticancer agents from bench to bedside.
Yamazaki S; Spilker ME; Vicini P
Expert Opin Drug Metab Toxicol; 2016; 12(3):253-65. PubMed ID: 26799750
[TBL] [Abstract][Full Text] [Related]
29. TranSynergy: Mechanism-driven interpretable deep neural network for the synergistic prediction and pathway deconvolution of drug combinations.
Liu Q; Xie L
PLoS Comput Biol; 2021 Feb; 17(2):e1008653. PubMed ID: 33577560
[TBL] [Abstract][Full Text] [Related]
30. IMPACT: a whole-exome sequencing analysis pipeline for integrating molecular profiles with actionable therapeutics in clinical samples.
Hintzsche J; Kim J; Yadav V; Amato C; Robinson SE; Seelenfreund E; Shellman Y; Wisell J; Applegate A; McCarter M; Box N; Tentler J; De S; Robinson WA; Tan AC
J Am Med Inform Assoc; 2016 Jul; 23(4):721-30. PubMed ID: 27026619
[TBL] [Abstract][Full Text] [Related]
31. Long range personalized cancer treatment strategies incorporating evolutionary dynamics.
Yeang CH; Beckman RA
Biol Direct; 2016 Oct; 11(1):56. PubMed ID: 27770811
[TBL] [Abstract][Full Text] [Related]
32. The clinical trial landscape in oncology and connectivity of somatic mutational profiles to targeted therapies.
Patterson SE; Liu R; Statz CM; Durkin D; Lakshminarayana A; Mockus SM
Hum Genomics; 2016 Jan; 10():4. PubMed ID: 26772741
[TBL] [Abstract][Full Text] [Related]
33. Mathematical modeling and computational prediction of cancer drug resistance.
Sun X; Hu B
Brief Bioinform; 2018 Nov; 19(6):1382-1399. PubMed ID: 28981626
[TBL] [Abstract][Full Text] [Related]
34. Roles of tumor heterogeneity in the development of drug resistance: A call for precision therapy.
Wu D; Wang DC; Cheng Y; Qian M; Zhang M; Shen Q; Wang X
Semin Cancer Biol; 2017 Feb; 42():13-19. PubMed ID: 27840278
[TBL] [Abstract][Full Text] [Related]
35. Intratumoral molecular heterogeneity in a BRAF-mutant, BRAF inhibitor-resistant melanoma: a case illustrating the challenges for personalized medicine.
Wilmott JS; Tembe V; Howle JR; Sharma R; Thompson JF; Rizos H; Lo RS; Kefford RF; Scolyer RA; Long GV
Mol Cancer Ther; 2012 Dec; 11(12):2704-8. PubMed ID: 22962325
[TBL] [Abstract][Full Text] [Related]
36. Computational approaches in cancer multidrug resistance research: Identification of potential biomarkers, drug targets and drug-target interactions.
Tolios A; De Las Rivas J; Hovig E; Trouillas P; Scorilas A; Mohr T
Drug Resist Updat; 2020 Jan; 48():100662. PubMed ID: 31927437
[TBL] [Abstract][Full Text] [Related]
37. Principles of Resistance to Targeted Cancer Therapy: Lessons from Basic and Translational Cancer Biology.
Sabnis AJ; Bivona TG
Trends Mol Med; 2019 Mar; 25(3):185-197. PubMed ID: 30686761
[TBL] [Abstract][Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
